AI assistant
CORCEPT THERAPEUTICS INC — Director's Dealing 2021
Feb 5, 2021
30681_dirs_2021-02-04_142532c5-7697-46de-a561-0d29629fcb4e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2021-02-03
Reporting Person: Lyon Joseph Douglas (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-03 | Common Stock | M | 25000 | $8.27 | Acquired | 25000 | Direct |
| 2021-02-03 | Common Stock | S | 25000 | $29.1828 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | Stock Option (Right to Buy) | $8.27 | M | 25000 | Disposed | 2027-02-10 | Common Stock (25000) | Direct |
Footnotes
F1: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.86 to $29.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2021.